Metformin use may be associated with decreased risk of prostate cancer
the ONA take:
According to a new study published in the journal European Urology, researchers have found that metformin use was associated with a decreased risk of prostate cancer diagnosis while other oral antihyperglycemics had no decreased risk.
For the nested case-control study, researchers identified 12,226 cases of prostate cancer among men residing in Northern Denmark between 1989 and 2011 from the Danish Cancer Registry and the Aarhus University Prescription Database.
They found that compared with never-users of metformin, metformin users had a decreased risk of prostate cancer diagnosis (adjusted OR = 0.84, 95% CI: 0.74 - 0.96). In addition, diabetics on no antihyperglycemics (adjusted OR = 0.98, 95% CI: 0.89 - 1.09) or on oral antihyperglycemics other than metformin (adjusted OR = 0.98, 95% CI: 0.86 - 1.10) did not have a decreased risk of prostate cancer. Insulin users also had a decreased risk of prostate cancer (adjusted OR = 0.77, 95% CI: 0.64 - 0.93).
Furthermore, among patients who had prostate-specific antigen (PSA) testing prior to 1 year before being indexed, metformin users had a decreased risk of prostate cancer versus nonusers (adjusted OR = 0.66, 95% CI: 0.51 - 0.86). In the same PSA-tested group, diabetics on no medication, other oral antihyperglycemics, or insulin did not have a significant reduced risk of the disease.
Metformin use associated with decreased risk of prostate cancer diagnosis.
- Prolonged Imatinib Therapy Improves Likelihood of Deeper Molecular Response
- Ruxolitinib Effective as Long-term Treatment Option for Polycythemia Vera
- Study Affirms Activity of Ibrutinib in Patients With R/R CLL With 17p Deletion
- Patients Receiving RT in APBI Facilities Despite Eligibility for Observation
- ASCO, ASTRO Issue Guideline Update for Postmastectomy RT
- Overall Benefits of Vaporized Nicotine Products Outweigh Harms, Says International Panel of Experts
- Sugar and Cancer: Mitigating the Affects of Diet on Cancer
- Nurse Residency Programs Can Impact Oncology Nursing Practice, Outcomes
- Tumor Markers (Fact Sheet)
- Implementing a Distress Screening Process for Cancer Patients
- Longer Maintenance Therapy Duration May Improve Survival in Myeloma
- HRQoL Better Maintained With Pembrolizumab in Ipilimumab-refractory Melanoma
- Economic Evaluation of Obinutuzumab in Combination With Chlorambucil in First-line Treatment of Patients With Chronic Lymphocytic Leukemia in Spain
- MRD Assessment Improves PFS Prediction in Patients With CLL
- Cancer Patients Have Unrealistic Hopes When Entering Clinical Trials
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|